Burning Rock Biotech Aims for 2024 Breakeven
Company Announcements

Burning Rock Biotech Aims for 2024 Breakeven

Burning Rock Biotech (BNR) has released an update.

Burning Rock Biotech Limited reported a decrease in first-quarter revenue by 11.9% year-over-year due to a strategic shift towards in-hospital testing, despite the segment’s own revenue growing by 11.3%. The company saw a significant decrease in operating expenses, contributing to a reduced net loss compared to the previous year. Burning Rock also indicated a breakeven target for 2024, adjusting to a new corporate structure with its headquarters now in Guangzhou.

For further insights into BNR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyBurning Rock Biotech, Dizal announce NMPA approval for sunvozertinib CDx
TipRanks Auto-Generated NewsdeskBurning Rock Biotech Announces Executive Changes
TheFlyBurning Rock Biotech CFO Leo Li resigns
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App